Pubblicazioni

ImmuneOncology-tyrosine kinase inhibitors combination, sometimes less is more

2021 - INTERNATIONAL IMMUNOPHARMACOLOGY

Stellato, M.; Santini, D.

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators

2021 - JOURNAL OF TRANSLATIONAL MEDICINE

Stellato, M.; Procopio, G.; De Giorgi, U.; Maruzzo, M.; Bimbatti, D.; Mennitto, A.; Sbrana, A.; Roviello, G.; Casadei, C.; Sepe, P.; Pignata, S.; Santini, D.

Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7)

2021 - AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS

Santini, D; Stellato, M; De Giorgi, U; Pantano, F; De Lisi, D; Casadei, C; Maruzzo, M; Bimbatti, D; Naglieri, E; Buti, S; Bersanelli, M; De Vivo, R; Di Lorenzo, G; Sbrana, A; Verzoni, E; Soraru', M; Fornarini, G; Mucciarini, C; Grillone, F; Mini, E; Vignani, F; Attademo, L; Pignata, S; Procopio, G

Metastatic Renal Cell Carcinoma Classified as Good Risk: The Easiest Choice Has Become the Hardest

2021 - CHEMOTHERAPY

Stellato, M.; Santini, D.